

REMARKS/ARGUMENTS

Claims 1-86 are pending claims. Applicant notes with appreciation that the Examiner has allowed claims 57, 60, 61, 64, 85 and 86. Claims 30, 47-56, 58-59, 62-63, and 81-84 are currently under consideration. Applicant respectfully requests reconsideration in view of the following remarks. Issues raised by the Examiner will be addressed below in the order they appear in the Office Action.

1. As requested by the Examiner, a copy of the revised abstract is hereby re-submitted (see page 3 of this response). In the previous Office Action, the abstract is objected to due to an informality. Specifically, it is objected to because the word “said” appeared twice in the abstract. In response, Applicant have amended the abstract to obviate the objection.
2. Claim 30 is objected to due to missing articles for the word “inhibitor” and the phrase “candidate inhibitor”. In response, Applicant has amended claim 30 to obviate the objection.
3. Claims 47-56, 58, 59, 62, 63 and 81-84 are rejected under 35 U.S.C. 112, first paragraph, for allegedly containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is mostly nearly connected, to make and/or use the invention. Applicant respectfully traverses. However, solely to expedite prosecution, Applicant has amended these claims to obviate the rejections.

Specifically, Applicant has amended claims 47-56 and 81-84 to specify methods for identifying candidate agents for FcRn-mediated drug delivery into the bloodstream when a formulation is administered non-intravenously. Support for the amendment can be found at least on page 25, lines 22-35 to page 26, lines 1-16 of the specification. Applicant has amended claims 48, 53, 58, 59, 62 and 63 to specify that the candidate agent is derived from an IgG Fc region, and amended claims 81-82 to specify that the FcRn binding partner is an IgG. Applicant submits that these amendments overcome the rejection. Accordingly, reconsideration and withdrawal of the rejection is respectfully requested.


CONCLUSION

In view of the foregoing amendments and remarks, Applicant submits that the pending claims are in condition for allowance. Early and favorable reconsideration is respectfully solicited. The Examiner is invited to contact the undersigned at 617-951-7000. A petition for a two-month extension of time, with authorization to charge the required fee to Deposit Account No. 18-1945, Order No. JMY-P01-002, is being filed concurrently. If a further extension is required, Applicant's attorney respectfully requests that such extension be granted and any fee required be charged to Deposit Account No. 18-1945, Order No. JMY-P01-002.

Respectfully Submitted,

Date: April 14, 2004

Customer No: 28120
Docketing Specialist
Ropes & Gray
One International Place
Boston, MA 02110
Phone: 617-951-7000
Fax: 617-951-7050



Weishi Li
Reg. No. 53, 217